Candidate peptide vaccine induced protection against classical swine fever virus.
Former investigations demonstrated that the envelope glycoprotein E2 could protect pigs from classical swine fever virus (CSFV). Based on these findings, we prepared synthetic peptide vaccine using E2 N-terminal antigenic units B/C and hoped to induce protective activity against lethal challenge of virulent CSFV strain Shimen. Five overlapped peptides sequence-covering amino acids 693-777 on E2 of Shimen were synthesized and then conjugated with bovine serum albumin (BSA), respectively. In the vaccination course, the candidate peptide vaccines in combination (multi-peptide vaccine (MPV)) were applied for immunization of pigs (n=10) and induced strong antibody response against CSFV. It is subsequently demonstrated that this peptide vaccine could provide immunized pigs complete protection against lethal CSFV challenge as C-strain does, while all non-immunized pigs in negative control group manifested obvious typical symptoms and died during the second and third weeks after viral challenge. In order to confirm the neutralizing activity of the polyclonal antibodies induced by MPV, neutralization assay were carried out on rabbits. The live C-strain alone could ordinarily induce typical fever on rabbits. The typical fever of rabbits induced by the live C-strain could be inhibited by pre-incubation with the anti-sera (dilution 1:4 and 1:16) induced by MPV, but not inhibited by pre-incubation with the same anti-sera from which the antibodies against five peptides were removed by peptide-specific affinity chromatography, which indicates that these peptide-specific antibodies in the anti-sera induced by MPV provided protective activity against CSFV. Our finding provides a new way to develop marker vaccine against CSFV.
Dong
Xiao-Nan
XN
Department of Biology, Research Center for Medical Science, Tsinghua University, Beijing 100084, PR China.
Wei
Ke
K
Liu
Zu-Qiang
ZQ
Chen
Ying-Hua
YH
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D015415:Biomarkers; D006691:Classical Swine Fever / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D006692:Classical Swine Fever Virus / Q000276:immunology* / Q000472:pathogenicity; D009500:Neutralization Tests / Q000662:veterinary; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000302:isolation & purification; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology; D014759:Viral Envelope Proteins
D000914:Antibodies, Viral; D015415:Biomarkers; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C087086:glycoprotein E2, classical swine fever virus